David Miklos, M.D., PhD Stanford University
David Miklos, M.D., PhD Stanford University Professor and Chief of BMT & Cell Therapy Program
Dr. David Miklos is the Chief of Stanford’s BMT and Cell Therapy Program that provides over 700 cancer cell therapies annually. Our allogeneic hematopoietic cell transplantation (alloHCT) research is optimizing graft content of HSC, conventional T lymphocyte, and regulatory T cell content in order to cure blood cancers via beneficial graft-v-tumor (GVT) immunity while reducing GVHD risk. Our CAR-T research provides the most direct targeting of cancer and is dramatically improving leukemia and Lymphoma with no GVHD risk. We are pioneering the combination of graft engineered allogeneic HCT with CAR-T benefit.
The Miklos lab has characterized allogeneic B cells and antibodies after blood transplantation. Our clinical trials established cGVHD therapeutic benefits using anti-B cell drugs rituximab and ibrutinib. We have developed human correlative assays to optimize CAR-T therapy including ctDNA MRD, tumor antigen quantification, CAR-T immune phenotyping (CAR-FACS), and their single cell RNA and DNA characterization.
Immunotherapy is revolutionizing cancer treatment and Stanford is developing, manufacturing and evaluating the most promising chimeric antigen T-cell (CAR-T) therapies targeting CD19, CD22, B7H3, GD2, and BCMA to benefit patients with cancer and autoimmunity problems.